Compounds > xamoterol
Page last updated: 2024-09-04

xamoterol and verapamil

xamoterol has been researched along with verapamil in 9 studies

Compound Research Comparison

Studies
(xamoterol)		Trials
(xamoterol)		Recent Studies (post-2010)
(xamoterol)		Studies
(verapamil)		Trials
(verapamil)		Recent Studies (post-2010) (verapamil)
269801717,6211,5272,067

Protein Interaction Comparison

ProteinTaxonomyxamoterol (IC50)verapamil (IC50)
Solute carrier family 22 member 1 Homo sapiens (human)6.8
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)0.2
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.297
ATP-dependent translocase ABCB1Mus musculus (house mouse)2
ATP-dependent translocase ABCB1Homo sapiens (human)2.2346
Cytochrome P450 3A4Homo sapiens (human)3.8008
Alpha-2A adrenergic receptorHomo sapiens (human)0.579
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)3.02
ATP-dependent translocase ABCB1Mus musculus (house mouse)10
Catechol O-methyltransferaseHomo sapiens (human)0.2
Potassium voltage-gated channel subfamily A member 3Homo sapiens (human)8
Histamine H2 receptorHomo sapiens (human)2.59
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.442
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.297
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)3.02
Sodium-dependent serotonin transporterHomo sapiens (human)0.24
Multidrug resistance-associated protein 1 Homo sapiens (human)5.598
D(3) dopamine receptorHomo sapiens (human)0.186
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.165
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)6.8
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)0.2
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.3945
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)0.2
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)0.175
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.1934

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19902 (22.22)18.7374
1990's2 (22.22)18.2507
2000's3 (33.33)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Lundström, T; Moor, E; Rydén, L1
Lewis, RV; McDevitt, DG; McMurray, J1
Briscoe, MG; Halliday, SE; Smith, HJ; Snow, HM1
Nagatomo, T; Sasaki, K; Shibata, A; Shimada, K; Wakabayashi, H; Watanabe, K1

Trials

2 trial(s) available for xamoterol and verapamil

ArticleYear
Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Adrenergic beta-Agonists; Aged; Atrial Fibrillation; Chronic Disease; Double-Blind Method; Electrocardiography, Ambulatory; Exercise Test; Female; Heart Rate; Humans; Male; Propanolamines; Ventricular Function; Verapamil; Xamoterol

1992
Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
    Journal of cardiovascular pharmacology, 1989, Volume: 13, Issue:1

    Topics: Adrenergic beta-Agonists; Aged; Atenolol; Atrial Fibrillation; Chronic Disease; Digitalis Glycosides; Exercise Test; Female; Heart Rate; Humans; Lactates; Male; Middle Aged; Propanolamines; Verapamil; Xamoterol

1989

Other Studies

7 other study(ies) available for xamoterol and verapamil

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Facilitation of calcium blocking and membrane effects by intrinsic sympathomimetic activity.
    Cardiovascular research, 1984, Volume: 18, Issue:1

    Topics: Adrenergic beta-Agonists; Animals; Atenolol; Calcium; Depression, Chemical; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Female; Heart Rate; In Vitro Techniques; Myocardial Contraction; Propanolamines; Propranolol; Verapamil; Xamoterol

1984
Cardiomyopathic hamster hearts: long-term effects of drugs on catecholamine contents and binding characteristics of alpha 1- and beta 1-adrenergic receptors.
    Biological & pharmaceutical bulletin, 1993, Volume: 16, Issue:7

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomyopathies; Catecholamines; Cricetinae; Heart; Ketanserin; Mesocricetus; Myocardium; Propanolamines; Radioligand Assay; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Verapamil; Xamoterol

1993